carbamates has been researched along with Cystic Fibrosis in 9 studies
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia." | 7.71 | Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. ( Milla, C; Moran, A; Phillips, J, 2001) |
| " Four trials (200 participants) are included: one short-term single-center trial (n = 7) comparing insulin with oral repaglinide and no medication in people with cystic fibrosis-related diabetes and normal fasting glucose; one long-term multicenter trial (n = 100, 74 of whom had cystic fibrosis-related diabetes) comparing insulin with oral repaglinide and placebo; one long-term multicenter trial (n = 73) comparing insulin with oral repaglinide; and one 12-week single-center trial (n = 20) comparing the long-acting insulin glargine to short-term neutral protamine Hagedorn insulin." | 4.93 | Insulin and oral agents for managing cystic fibrosis-related diabetes. ( Onady, GM; Stolfi, A, 2016) |
| "Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia." | 3.71 | Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. ( Milla, C; Moran, A; Phillips, J, 2001) |
| " In another study using the same dosage regimen, amelubant appeared to be safe and well tolerated." | 2.43 | Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. ( Schmitt-Grohé, S; Zielen, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Onady, GM | 2 |
| Stolfi, A | 2 |
| Giacomini, D | 1 |
| Martelli, G | 1 |
| Piccichè, M | 1 |
| Calaresu, E | 1 |
| Cocuzza, CE | 1 |
| Musumeci, R | 1 |
| Ballmann, M | 2 |
| Hubert, D | 2 |
| Assael, BM | 2 |
| Staab, D | 1 |
| Hebestreit, A | 1 |
| Naehrlich, L | 1 |
| Nickolay, T | 1 |
| Prinz, N | 1 |
| Holl, RW | 2 |
| Döring, G | 2 |
| Bragonzi, A | 1 |
| Paroni, M | 1 |
| Aktürk, FF | 1 |
| Cigana, C | 1 |
| Schmidt, A | 1 |
| Gilpin, D | 1 |
| Heyder, S | 1 |
| Born, T | 1 |
| Smaczny, C | 1 |
| Kohlhäufl, M | 1 |
| Wagner, TO | 1 |
| Loebinger, MR | 1 |
| Bilton, D | 1 |
| Tunney, MM | 1 |
| Elborn, JS | 1 |
| Pier, GB | 1 |
| Konstan, MW | 2 |
| Ulrich, M | 1 |
| Heltshe, SL | 1 |
| Lands, LC | 1 |
| Hilliard, KA | 1 |
| Koker, P | 1 |
| Bhattacharya, S | 1 |
| Staab, A | 1 |
| Hamilton, A | 1 |
| Kronfeld, K | 1 |
| Honer, M | 1 |
| Schmitt-Grohé, S | 1 |
| Zielen, S | 1 |
| Moran, A | 1 |
| Phillips, J | 1 |
| Milla, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus[NCT00662714] | Phase 3 | 73 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carbamates and Cystic Fibrosis
| Article | Year |
|---|---|
Drug treatments for managing cystic fibrosis-related diabetes.
Topics: Administration, Oral; Bias; Blood Glucose; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Fasting; | 2020 |
Insulin and oral agents for managing cystic fibrosis-related diabetes.
Topics: Administration, Oral; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Humans; Hyperglycemia; Hypogly | 2016 |
Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
Topics: Adolescent; Amidines; Asthma; Bronchial Hyperreactivity; Carbamates; Child; Child, Preschool; Clinic | 2005 |
3 trials available for carbamates and Cystic Fibrosis
| Article | Year |
|---|---|
Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Carbamates; Child; Cystic Fibrosis; Diabetes Mellitus, | 2018 |
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
Topics: Adolescent; Adult; Amidines; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Carbamates; Chi | 2014 |
Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus.
Topics: Adolescent; Algorithms; Carbamates; Child; Cystic Fibrosis; Diabetes Mellitus; Early Diagnosis; Huma | 2014 |
3 other studies available for carbamates and Cystic Fibrosis
| Article | Year |
|---|---|
Design and Synthesis of 4-Alkylidene-β-lactams: Benzyl- and Phenethyl-carbamates as Key Fragments to Switch on Antibacterial Activity.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbamates; Cystic Fibrosis; Drug Design; Gram-Negative Bacteri | 2017 |
BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.
Topics: Adult; Amidines; Animals; Anti-Inflammatory Agents; Bacteremia; Carbamates; Cystic Fibrosis; Disease | 2014 |
Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.
Topics: Adult; Blood Glucose; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Female; Food; Humans; Hypoglyc | 2001 |